KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Cash & Current Investments (2016 - 2025)

Nektar Therapeutics has reported Cash & Current Investments over the past 16 years, most recently at $245.8 million for Q4 2025.

  • Quarterly results put Cash & Current Investments at $245.8 million for Q4 2025, down 3.71% from a year ago — trailing twelve months through Dec 2025 was $245.8 million (down 3.71% YoY), and the annual figure for FY2025 was $245.8 million, down 3.71%.
  • Cash & Current Investments for Q4 2025 was $245.8 million at Nektar Therapeutics, down from $270.2 million in the prior quarter.
  • Over the last five years, Cash & Current Investments for NKTR hit a ceiling of $1.0 billion in Q1 2021 and a floor of $175.9 million in Q2 2025.
  • Median Cash & Current Investments over the past 5 years was $391.0 million (2023), compared with a mean of $477.2 million.
  • Biggest five-year swings in Cash & Current Investments: crashed 40.68% in 2022 and later grew 10.52% in 2025.
  • Nektar Therapeutics' Cash & Current Investments stood at $734.0 million in 2021, then tumbled by 31.2% to $505.0 million in 2022, then crashed by 39.88% to $303.6 million in 2023, then fell by 15.94% to $255.2 million in 2024, then fell by 3.71% to $245.8 million in 2025.
  • The last three reported values for Cash & Current Investments were $245.8 million (Q4 2025), $270.2 million (Q3 2025), and $175.9 million (Q2 2025) per Business Quant data.